CF
FHTX icon

Corebridge Financial’s Foghorn Therapeutics FHTX Stock Holding History

Corebridge Financial’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,373
Closed -$45.2K – 986
2025
Q1 		$45.2K Sell
12,373
-184
-1% -$839 ﹤0.01% 2756
2024
Q4 		$59.3K Sell
12,557
-948
-7% -$6.91K ﹤0.01% 2782
2024
Q3 		$126K Sell
13,505
-82
-0.6% -$594 ﹤0.01% 2483
2024
Q2 		$78.1K Buy
+13,587
New +$80.9K ﹤0.01% 2728

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Corebridge Financial's FHTX Position: Q2 2025 in Review

Corebridge Financial sold out of Foghorn Therapeutics (FHTX) in Q2 2025, closing a stake of 12,373 shares — an estimated $45.2K sold.

Corebridge Financial first reported a position in FHTX in Q2 2024 and held it in 4 quarters. The position peaked at $126K in Q3 2024. 81 funds tracked by Wall St. Rank hold FHTX as of Q2 2025.

  • Corebridge Financial reported no remaining Foghorn Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 12,373 Foghorn Therapeutics shares in Q2 2025, an estimated $45.2K.
  • Corebridge Financial first reported a position in Foghorn Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Foghorn Therapeutics position peaked at $126K in Q3 2024.
  • 81 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.